, ritis and rheumatism.
`2, no. 9, suppl. (Sept. 1999)
`) - General Collection
`AR95163
`eived: 10-14-1999
`
`I...marl/m=1v r:z• MEDIC t4
`
`SRE; =IIC
`
`Vo me 42, No. 9 (Supplement) September 1999
`
`• iWp."P g
`1V
`.t.
`r
`
`r,
`
`10.t.11.*
`t'0;lit$*$4..WY1.6"17PNA&
`
`

`

`AMERICAN COLLEGE OF RHEUMATOLOGY
`63" Annual Scientific Meeting
`
`ASSOCIATION OF RHEIPMATOLOGY HEALTH PROFESSIONALS
`34th Annual Scientific Meeting
`
`November 13 — 17, 1999
`
`Hynes Convention Center
`Boston, Massachusetts
`
`ACR/ARHP PROGRAM OBJECTIVES
`
`• To provide an in-depth presentation of the recent advances in the diagnosis,
`management and treatment of rheumatic disease.
`• To provide a forum for exchange of new research data by scientists/investigators
`working in the area pf rheumatic diseases.
`• To provide an opportunity to interact with experts in small group sessions.
`• To provide an opportunity to update knowledge concerning available pharmaceutical
`products and medical and assistive devices for use in the management of
`rheumatic diseases.
`
`The American College 01 Rheumatology is accredited by the Accreditation Council for Continuing Medical Education
`(ACCME) to provide continuing medical education for physicians. The American College of Rheumatology takes
`responsibility for the content, quality, and scientific integrity of this CME activity and designates this continuing
`medical education activity for a maximum of 57.50 credit hours in Category 1, Level One of the Physician's Recognition
`Award of the American Medical Association.
`
`This program is being sponsored by the American College of Rheumatology for educational purposes only. The
`material presented is not intended to represent the only or the best methods appropriate for the medical
`situations discussed, but rather is intended to present the opinions of the authors or presenters which may be
`helpful to other practitioners. Attendees participating in this medical education program sponsored by the
`American College of Rheumatology do so with full knowledge that they waive any claim they might have
`against the ACR lbr reliance on any information presented during these educational activities.
`
`at the NLM and may be
`Subject US Copyright Laws
`
`

`

`American College of Rheumatology
`
`SCIENTIFIC PROGRAM
`
`AMERICAN COLLEGE OF RHEUMATOLOGY •
`63"1 Annual Scientific Meeting
`
`ASSOCIATION OF RHEUMATOLOGY HEALTH PROFESSIONALS
`34th Annual Scientific Meeting
`
`November 13 - 17, 1999
`
`Boston, Massachusetts
`
`Copyright © 1999 by the AMERICAN COLLEGE OF RHEUMATOLOGY, Atlanta, Georgia
`
`This material was copied
`at the NMI and may ere
`Subject US Copyright Laws
`
`Ex. 1109 - Page 3
`
`

`

`TABLE OF CONTENTS
`
`ACR ABSTRACT CONCURRENT SESSIONS (continued)
`TUESDAY (4:00 PM — 5:30 PM)
`Juvenile Idiopathic Arthritis — Soluble Factors as Critical
`Mediators (Abstracts # 1938 — 1943) (cid:9)
`Fibromyalgia (Abstracts 1944 — 1949) (cid:9)
`ACR/ARHP Combined Rehabilitation (Abstracts # 1950 — 1955) (cid:9)
`Infection Related Rheumatic Diseases (Abstracts # 1960 — 1965) (cid:9)
`WEDNESDAY (10:30 AM — 12:00 PM)
`RA: TNF — Blockade (Abstracts # 1977 — 1982) (cid:9)
`Spondyloarthropathies (Abstracts # 1983 — 1988) (cid:9)
`Sjogren's and Myositis (Abstracts # 1989 — 1994) (cid:9)
`Advances in OA Therapeutics (Abstracts # 1995 — 2000) (cid:9)
`Cytokines and Mediators (Abstracts # 2001 — 2006) (cid:9)
`Patient and Public Education (Abstracts # 2007 — 2012) (cid:9)
`Apoptosis and Handling of Apoptotic Cells (Abstracts # 2013 — 2018) (cid:9)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`ACR MINISYMPOSIA
`Sunday (2:15 PM — 3:45 PM)
`Stem Cell Transplantation in Rheumatic Disease (Abstracts # 593 — 597) (cid:9)
`Novel Approaches to Biological Response Modifications in
`Rheumatoid Arthritis (Abstracts # 598 — 602) (cid:9)
`TUESDAY (4:00 PM — 5:30 PM)
`Angiogenesis (Abstracts # 1956 — 1959) (cid:9)
`
`ARHP ABSTRACT SESSIONS
`Sunday
`
`Patient Education and Public Health (Abstracts # 603 — 608) (cid:9)
`MONDAY
`
`Self Care and Health Status (Abstracts # 1240 —1245) (cid:9)
`Pediatric Rheumatology (Abstracts # 1246 — 1251) (cid:9)
`Ethnicity and Outcomes (Abstracts # 1288 — 1292) (cid:9)
`Lower Extremity Pathomechanics and Function (Abstracts # 1293 — 1298) (cid:9)
`
`S394
`S395
`S396
`S397
`
`S400
`S401
`S402
`S403
`S404
`S405
`S406
`
`S169
`
`5170
`
`S397
`
`S171
`
` S277
` S278
` 5285
` S286
`
`S6
`This material was copied
`at the NLM and may be
`Subject US Copyright Laws
`
`Ex. 1109 - Page
`
`

`

`TABLE OF CONTENTS
`
`ARHP ABSTRACT SESSIONS (continued)
`
`Tuesday
`
`Research Methods (Abstracts # 1571 — 1573) (cid:9)
`
`The New Generation of Arthritis Web Sites: What
`
`Your Patients Know, What You Ought to Know (Abstract # 1574) (cid:9)
`
`Current Topics in Nursing (Abstracts # 1902 —1913) (cid:9)
`
`Clinical Rehabilitation (Abstracts # 1950 —1955) (cid:9)
`
`
`
`
`
`
`
`
`
`Impact of Rheumatic Disease on Individuals and Families (Abstracts # 1966 — 1971) (cid:9)
`
`Abstract Author Index (cid:9)
`
`Subject Index (cid:9)
`
`
`
`
`
`S333
`
`S333
`
`S388
`
`5396
`
` S398
`
`S408
`
`S447
`
`This material Ws copied
`at the N LM and may be
`Subject US Copyright Laws
`
`

`

`1973
`
`1976
`
`ALENI)RONATE liOlt '1111! TRIIATMENT 011 OSTEOPOROSIS IN
`SAIWI'Y AND III,F1CACY (cid:9)
`ralchil, 51 Bard:ire. P Zoltan, I. Lepore, A
`14.1)1A1RIC RHEUMATIC DISEASES. Ii (cid:9)
`110011Compagill, M I. !Ranch' Trieste, Genova, Italy, Milano, Italy
`secondary osteoporosis with b1SpliOSplionateS is well established hi adults, but
`
`Treatment or
`clinical studies In the pediatric age are Binned.
`All open Multicenter prospective study was perlbrined to assess safety and efficay of Mends/nate
`(> 6 months)
`Cltildrcli With rheumatic diseases. To he included. patients had to he on chronic
`In
`col-Oct/steroid treatment or to have a low bone mineral density. Fort rihree patients (30 females, 13
`males) completed the study. Diagnoses were juvenile arthritis (17), SLR (12), (lermatoniyositis (7),
`other (7). Mean age at Study entrance was 12.9 -1- 3.7 years; Id patients had already reached
`!pubertal maturity, Alendronitie was administered orally at the daily dosage of 5 or 10 mg. Baseline
`V11.12.14V2C411.11.1: Cy11111311141m.
`Z-scores ranged from - 1.3 to -5.3, Each patient underwent sefgn (cid:9)
`lei inie n-,s.ri,deicfil‘f/e
`Standard 1)10C11clitiCal lest were performed at each participating center, while was
`
`parameters were meteifired centrally. Lumbar spine bone minced delISIty i,
`every c ::::rn,t,Ii priswmn,lithyre,XA. using a standardized protocol, cross-calibration of instruments, (cid:9)ents, an 6
`
`r
`tsc of bone mass in all children, with an average 111111) itierease
`
`r( ,,f•
`
`
`patients obtained a normal BAB) value. htmlI comparison, the
`of (cid:9)
`(luring the year' immediately preceding the
`average 11).11) in 15 or the patients of the study (cid:9)
`Ilcight increased by an average or.1.3 (cid:9)
`3.7
`increased by only I (cid:9)
`
`•onset ri ngedronate therapy (cid:9)
`
`(cid:9) the study period. SC1.11,11 1111,11111C 1)111,11311111111, (IL-CI-Cased by 16.3 :t 11 .2':i, and urinary,
`cm (lui
`procollagen telopepirde by 26.8 x 17.8%. Knee radiographs perfor'me'd in prepubertal children
`showed absence of rickets and presence or inclaphyscal lines. The drug was Well tolerated, except
`roli oceaslOnal abdOmilial pain and one episode of esophagitis.
`We cifildtgle that alciitlfifitafc Can be safely administered even in the pediatric age, and dual it
`
`is)igti,i,ii,ipe,;:rnotlsii,,linproves bow: mass In Children or adolescrilesnfithotne(wAni)let diseases and secondary ,,
`
` 1111/ jc:irtsilitc-s tts s1111,7).6 after a I (cid:9) ,i wael stt)1,/x‘tr( )ti::,, (cid:9)i2 tit 1
`
`
`
`
`d
`
`II:14 KINASE 2 (IKK2) IS A KEY REGIII.ATt /It (IF SI'N()VIAL INFLAAIMATION. P '1'ak, I) Al Gerlag,
`I) A van de Gull, K II Aupperle, 11 I. Bennett, A Al Manning, (i S Firestein La Jolla, CA
`
`Introduction. NE-kli is a key regulator of inflammatory gene transcription and plays an
`import:hilt role in the pathogenesis or rheumatithl arthritis. NF-k)4 tictivailim in synoviocytes is
`controlled (cid:9)
`IKK2, which initiates Ildt (lc-gradation. Subsequently, NIckli is released from
`cytoplasmic Ikli and is tismslocated to tile nucleus. In contrast, the other key memlier of lie WI(
`complex, IKK), is 1101 involved in synoviiwyie NE-kli act ivat km. In these studies, we examined the
`effects of IKK2 :Ictivotion and suppression on adjuvant arthritis (AA).
`Methods and Itesults. (cid:9)
`synovioeyles (111.5) were Mitally Infected with an
`adentiviral vector expressing a tioniinaill negative IKK2 gene (UN-IKK2) containing a K.-.111
`Mutation. 'fronsgette expression ivas driven by the CAW promoter. hiummolluoreseence (lemon-
`, sioxf. (cid:9)
`cbg ceposiljztut (cid:9)
`(ks. LIN. 1.4J2212141.V2, (cid:9)
`,24242.1)10P1,24. domes WRAVSZL
`im.,21)11..1 noclear translocation of (cid:9)
`in transclucc(1 EIS stimulated for I hr with TNIc-it (100
`it/n1). AA was ititluce(1 in 1.eivis rats with if, /////erc///oxis lit mineral oil. I)N-IKK2 (11=15) or
`control ailenoviral construct expressing green fluorescein protein (GI'P) (n=15) was Injected
`intro.artietdarly In the right ankle on day I2, Paw swelling was measured by plethysmometry. After
`I week the mean Increase In the volume oldie right paw was 1.05±0.12 ml In the 1)1V-IKK2 treated
`rats c-intipared (cid:9)
`1,39=1072 nil ill ille control rats (1) 0.02). Inmrovement was also notett 111
`the Luling:Lae(' paws of 1)N-IKK2-ireateit aiiimols, suggesting a "COntralalcral ell/el". An allenoviral
`constenct encoding the wild type (wt) IKK2 gene, which is constitutively activated when
`overespiessed in cells, was Olen Injected into normal rat joints. SVI-IKK2 gene transfer resulted in
`tinkle cryiltutint and significant pan" s)relling compared \5't)) the contralateral joint an,' GIP-treated
`rats (It -11.0.5). I listologle evaluation revealed synovial mononuclear Infiltration and intimal lining
`hyperplasia in animals injected willi wild type IKK2 hut nol in the OP-treated rats.
`Conclusion, Blocking (cid:9)
`gene therapy with o cloinintint negative IKK2 motant ameliorates
`rat AA, whereas lateatom Ois NliAli by wild type IKK2 in vivo induces arthritis in normal rats. These
`data suggest that IKK2 plays a central role in the pathogenesis of arthritis.
`
`1)iscl()suret work reported In Otis al)stract was supported 1)y;
`Signal Pharmaceuticals
`
`1974
`
`IiihiltiNtL\1(>1)111A9'ION (II' EXI'liltIMENTAL CIILAMY1)1A-ASSMIATE) REACTIVE ARTHRITIS.
`Judith A Whittom-1 liaison, Ilene Gerard, Erin Davis, Cary Voro, W ,Mark Saltzman, Elizabeth
`Stuart, II Ralph Schumacher, Alan I'lluclson Detroit, All, Anthers!, AI& Ithaca. NS', gliiladcliMia, PA
`
`We previously reported tleveltpillent or a tilltrine model or Chlantydia-associated reactive
`arthritis. Following experimental ocular tn: genital infection with limn:ill biovars or r..bidiliyella
`the organism disseminate,: to synovial tissue and IllslopitiliolOgie signs of synovitis
`develop. We tested whether immunization with nn anifehlattly(lial vaccine candidate Mine to
`Intel:lions challenge modulated joint Inflammation. (:311/11e1 'nice (5-8/treatnieni group) were
`immunized with a itionocional (cid:9)
`aillillody (iliA1/2) which is a ilioleetilar Mimic or the
`rhlamydial exoglycoliiii(1 antigen II il.XA). We demonstrate(' previously in mice that this vaccine
`131-OIL-cis against ocular cltlan)ytlitil infection. In the present sunlit's, we compared the oral,
`intranasal, and stibctitimeous rottleS for delivery of niA1,2 encapsulated in poly (lactic aci(1)
`mierospheres. Alter lion Immunizations (-) pg n1A1)2/closc) out Confirmation 111,11 positive controls
`here serum positive for :tot i-GI.XA Al) liy 111.15A, all mice and recipients of normal 1,/-,(11 or nothing
`were topically challenged intravaginally with K scrovar or C Intelmmolls (2000 'IC:1)50). Vaginal
`swaths were titkeil weekly for !hies/biologic assays. Eight-10 inks finer, MiCe were sacrificed and
`tissues processed for IliStOlOgy Or 11301eCtilar analyses for chlami-(11:11 genes. Infectious loads were
`significantly reduced by oral InummizatIon even al (1.7 p.i.; (cid:9)
`(1.1-b, all 1111111111/inal mice allOWCLI
`Significant reductions which correlated with reduce(' genital islet i»Ilammatitm at 8-111 wks. Knee
`pathology was assessed in a masked fie:10011. The 1,tA1)2 vaccine recipients all slit/int:LI highly
`significant redUclion (i)<mo ) In SyntiVIal histOpalliologic scores: die major differenee front
`controls was a marke(1 redact ion in synov lid itionoeyie infiltration. ( /rill immunization WaS the must
`pet/It:Clive by all criteria tested. Screening1/I:Ron harvested tissues (lid not (listingush altered levels
`of organism in genital tract or synovitun hosed on vaccination and competitive PC11 will be used for
`this. ( >or results shoiv thal the nlAb2 vaccine reduces acute (cid:9)
`infection as well as the
`synovial inflitillinalion associated will clissetninatell inlet:11On. Current studies are testing whether
`tin: (cid:9)
`11-111.1CCS LliSSemIttaijon directly (cid:9)
`by re(luction (cid:9)
`synoyial inliallinialory
`responses.
`
`Inselostirei ivork reported in ads ilbstratA was supported by;
`
`ACR Abstract Concurrent Session
`RA: TNF—Blockade
`Wednesday, November 17, 1999, 10:30 Am-12:00 PM
`
`1977 (cid:9)
`EFFICACY OF '111II FULLY HUMAN ANTI-TNE ,INTIIIODA 1)2E7 IN RHEUMATOID ARTHRITIS. I.
`11A van de Butte, li Rau, P C Breedveld,,) 11 Kaltlen, NIG Malaise, di St:limit:I/kin-1min% I) Emery, (i It
`Iltirillt-SILT, I I ZdtlIcr,11 II NIollISOp01110S, I) COIllpagnotte, J KL-11113C111, 11 Kopper The Netherlands,
`Germany, Belgium, United Kingdom, ()recce
`Objective: Dose-finding phase II study comparing 3 dose levels of 1)2E7 and plat:L-130 over
`months in patients with long standing active rheumatoid arthritis.
`Atethodst A total of 283 patients were included in this randomised double-blind, placebo-
`least 4 weeks before study treatment. Patients
`controlled study. DMARDs were cliscontina,; (cid:9)
`
`N3vi,:it.:,k,l,),itid,,telesi Or either 1>21,7 at 20, -SO, 80 mg
`(,„ (cid:9)
`ra
`placchu by' subcutaneous (s,c) sell' injection for
`Results; Overall patient CbaraCterislies at baseline (Medi:111): age 53 years, (Mullion of RA ii years,
`I, -I previous IA121)$. Clinical responses after 3
`MI
`
`nun/h, CUP 51 WW (cid:9)OWN, 1-1,"!')(; 30, litilt (cid:9)8.
`
`summarised below based on 11-1' analysis:
`
`w, or ins achieving ACR 20 response
`Median % improvement In '111:
`Median 'X iniprOVeillent in SW,i(l
`Median (cid:9)
`improVeillent in C1111
`
`Placebo
`
`(n=70)
`Ill
`5
`IS
`
`)2II7 (cid:9)
`
`20 nig
`(n=71)
`49
`57
`42
`55
`
`1)2117 (cid:9)
`
`1)2E7
`
`40 mg
`(1)=70)
`57
`61
`59
`67
`
`till mg
`(11=72)
`56
`55
`61
`65
`
`Conclusion; For all Olicacy parameters studied, all (loses of 1)2117 were StallStically significantly
`superior to placebo (p i. 0.001). 20, III nil 8l) ing/iveck were nearly equally efficacious when
`given s.c. In patients with active RA.
`
`Disclosure: work reported In this abstract was supported by:
`Grants supporting this work: Arthritis Foundation (11V.111, (cid:9)
`Hirsh Foundation (ESS), Mill
`ALI-I-193 ()WTI). All 125-i I (APB), and GM i 1873(\VMS).
`
`Disclosure: work reported in this abstract was supported byi
`Stiuly sponsored by Knoll Ali, Ltalsvigshafen, Germany
`
`1975
`
`1978
`
`c,1.1)(.()SAAIINIt SI t1.1tATIt sit (cid:9)
`It111,1•Clts ItItt)tiltit5sItn4 ()lt 001ilt ()STI,()A tat nuns (111111 3 vititts: A
`N.Attill04.0yrittn.l.F.1). 1)1 n'lll.g111.INI), ItIttls1,1,(:fleft TIU,11. J.1' licginsittr, it 1)crois)•, 1
`(11.1t (cid:9)
`1..111.1 1).tcre, I. C Ilnv.nl. C Gossul
`
`Pattl, It I. let', 1'. (cid:9)
`
`Background. Ititstats or dintral I nal) support a mkt for Om (1,111inv millate as a symptom 311111111111111)1114 In osic.ranhrlus
`f(lA).'1111, study (cid:9)
`Ito too the longlvoi, vocals of Ow tli vg ill the pEoprt's,lon (cid:9)
`loict: (/, \ joint sloirtot-al rlhitigos
`antl N)1111/tolti, 111villoils..! 12 paticois (cid:9)
`knvt. (cid:9)
`Alit trittoi.0 o cm. randomly as•agord. in / double-blind 111,1,11m.
`11111/1111111/1/11 11,11111311 Willl /1,11 011011,1111111C N1111.111: 150011114 MI( 3,111.1)1 Or 111.1,1111/ 11,, 3 (cid:9)
`vars. M'cip.111 hcaring,
`.11111:11, pi qt•ritri.Litliogrlillis 4,1111 1,11, ss,rc 1331:11 (cid:9)
`1:11111111131111 mitt an, I 0013 )»ais 1.1.11111.111,111,11/npaltunt
`anti rtli,igraphiv (cid:9)
`tot...111AM S1/.1, 11111111 (.ISW) (cid:9)
`;;;;;;;;a t omparn,lon or (cid:9)
`tibia kmoral join, /vas
`aNst-,ad 111 tlig11.11 filmy,: .11.11111,1/y .1 valitEot-ticompottlimAl alorillim, wall 111, namovt.,, toctlial joint spa,' a1 coroloitmt
`lxtoo token for ill,' 1/1 imary t't altEloon 1,0E11 pis). 1,)11/ottnos /vore st-ort.t1 at caul, 11111111111 311,11 11111 1113. (11/1.11) V1()31,3(/
`"' (cid:9)
`//11/1111g 111 (cid:9) P/11-'111/16./11 ( PP) /1/1/111.1111 1111 .i.Y1,11. /1111,P,/,', 11,11°
`lttlt11/1110.11,11 111T/131,11, /11111,1110g all 1,111011111SW 13111V1113 6p We 1.1,113/1/3r113.1111/133111111:1141111W.1131. test ht. '1111. 1,311
`it.'.11)11 1.11 ilk, 1'.11411I'‘ '11‘ h "1.31 ‘1"‘.1'1111"' 1hr 113,1111111,1111113,11(1 tliscast/ c11.1r.it/crotit,. Platrho Ovatt.t1 palicnts 13111.111
`1131/1,1111111 ,11.11. , 11.1131113,11,1 (11N) 01 apt»»Nituatuly wino) (cid:9)
`while 1111.151/4 o(LunIal 11, Ilia (am (cid:9)
`A111.tic
`/(.11113. A slight ,veneniiill In yaipollus sv.ei evident at the end (cid:9)
`with lasos, ..0;;;;,.11.-.4
`as.,11;sa..mss,..sna,
`PP (cid:9)
`
`I'l'l' (cid:9)
`
`1.1'1.
`
`)Sin toirollnott (oni)
`.150 3 (cid:9)
`(111111)
`MINIM. V111,11111'111
`
`1.P
`{.mar„n4 scan
`
`lhotet 111,')1',l 1',ll,rl at 101,10 (SE, "I gq00100,011101102.0.01114 i014s001;
`nor.- (I 1/311, ')/ 0.111r. 1111 0.11 (cid:9)
`"I' 1E1/ 1 us. 111.1,111/ 0AN()V/1 /
`Camelot:Ions. taittibino.1 /itructory and Synipiont (cid:9)
`vlft•cls stlitgvht 11,11 glOcoNantior sell,i,c 111.p' he a
`pos-able 13/..case Nimbi) tut, .gavel 111 (M.
`
`1)Isclostirei work reputed In Ads aluoluct was supported lip
`wink IL-ported in 1111,11/N11111, WAS N11111111/113,1 (cid:9)
`11110,1 lil,31.1101 Group
`
`1)2117 SLOW!. 1(A)I().
`WITII TIIII FULLY IIDMAN (cid:9)
`(.1611'111C )ISIIASII PItO(iltlISSR)N IN ID RADIATOR) ARTHRITIS. 11 Rao. (1 Ileiborn, (cid:9)
`Sender, I.
`11A van de Nate, PLC van Mel, A den Itroeder, Al Sehattenkireliner,) (cid:9)
`NI 111111,11 Fenner,
`J Kempeni, II Kopper (Icrmany, The Netherlands, Switzerland
`
`(H)Ject 'vet Longt ern) study of the effect 111'112E7 on radiographic disease progression in patients
`ivith long standing active rheumatoid arthritis (M).
`Methods: Patients were treated with Iv )21:7 doses from 0.5 It/ I11 mg/kg for one year mostly at
`biweekly intervals (study )12011I/00.), 66 patients with a complete Sl-1 01'X-:Os 01.111111(1S, wrists and
`Iseet 'alien at baseline, 6 and 12 months were evaluated . Additional X-rays preceding /nutty entry
`(provaltie, mean minus 19 months) were available for 22 Milli:MN from the Ratingen centre to
`compare the progression rote pre and (luring treatment with 1)2E7. X-rays were real setwlse
`blinded to patient identity and sequence of the films.
`Itesultst Mean radiographic score values over time are summarised for the total study lit/Imitation
`SS) as well as for the subgroup with preceding X-stys Ut = '22).
`
`All centres (cid:9)
`
`(i1=-66) (cid:9)
`
`Centre (cid:9)
`
`Italingen (cid:9)
`
`Mean RA duration
`Ratingen Score (0)-190) (cid:9)
`Sharp erosion score (0220)
`Sharp JON score (0-168)
`
`Baseline
`(12.1 yrs)
`-17.(1
`59,2
`53.9
`
`12 months
`(1 3.1 )'rs)
`.16.7
`59.1/
`55.0
`
`Pre•valtiv
`(10,2 yrs)
`3.1.6
`-13.9
`:15.5
`
`Baseline
`(11.8 yrs)
`-11.2
`52.3
`51.7
`
`(n= 22)
`
`12 months
`(12.11 yrs)
`-11.4
`52.3
`53,5
`
`During the treatment with 1)2117 1,t evidence for radiographic progression was observed In
`contrast to the preceding time period with DMARD Ire;11111L-111 where a deterioration was obvious.
`Conclusion: The data suggest 1)217, a fully hunts 1111t1•TNI' 1111i113()(1y, slows disease progression
`In RA, This result warrants further evaluation,
`
`Disclosure: work reported in Ibis abstract was supported by.
`Study was supported by Knoll AG, lan.1)yigshaten, Germany
`
`This mate ria IS,40aviad
`
`at the NW and may be
`
`Subject US Copyright Laws
`
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`